Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefepime-zidebactam vs. Meropenem in Complicated Urinary Tract Infection or Acute Pyelonephritis
NCT04979806Phase 3Completed
- Sponsor
- Wockhardt
- Start
- Aug 2022
- Primary completion
- Nov 2024
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of cefepime + zidebactam in complicated urinary tract infection (cUTI) and acute pyelonephritis (2 arms), sponsored by Wockhardt. Primary endpoints: Overall Success at Day 17 and Treatment-Emergent Adverse Events at Day 26. Started Aug 2022; status: completed.
02
Drugs
cefepime + zidebactam
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on NCT04979806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04979806.